ClinicalTrials.gg
CompletedNCT00561080Updated Jan 11, 2019Results posted

Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)

A Phase 3 interventional study of Zostavax in Prevention of : Herpes-Zoster, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
759
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Chickenpox Vaccine in Herpes Zoster — none open to participants now, none under way, none of them phase 3. Chickenpox Vaccine · Herpes Zoster.

Enrollment
5th of 29
759 · median 160
Started
2007
with 3 others
Phase 3
9 of 29
none open now
Registered
7th of 29
by date
Lead sponsor
15 of 29
Merck Sharp & Dohme LLC

Among the 29 studies testing Chickenpox Vaccine in Herpes Zoster, this one is the 5th largest by enrollment, is one of 4 that started in 2007, is one of 9 in phase 3, and was the 7th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 29 studies testing Chickenpox Vaccine in Herpes Zoster is open now. The open studies under Herpes Zoster, anywhere →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 70 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies testing Chickenpox Vaccine in Herpes Zoster as a file.
02

Study summary

Primary objective:

Immunogenicity To demonstrate that a second dose of ZOSTAVAX® elicits higher varicella-zoster virus (VZV) antibody titres than a first dose of ZOSTAVAX® whether given as a 0-1 month schedule or as a 0-3 month schedule in subjects ≥70 years of age as measured at 4 weeks post-vaccination

Secondary objectives Immunogenicity

  • To summarise the VZV antibody titres at 4 weeks post-vaccination after a 1-dose regimen and 4 weeks post-vaccination after each dose of each 2-doses regimen of ZOSTAVAX®.
  • To compare the VZV antibody titres at 12 months after completion of a 1-dose regimen with the VZV antibody titres at 12 months after completion of each 2-doses regimen of ZOSTAVAX®
  • To summarise the VZV antibody titres at 24 and 36 months after completion of a 1-dose regimen and at 24 and 36 months after completion of each 2-doses regimen of ZOSTAVAX®
03

Conditions studied

  • Prevention of : Herpes-Zoster

Browse trials for

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 70 years
  2. Varicella history-positive or residence for > 30 years in a country with endemic VZV infection
  3. Signed form prior to any study procedure

Exclusion criteria

Exclusion Criteria:

  1. Febrile illness within the last 72 hours before the first vaccination
  2. Prior herpes-zoster episode clinically diagnosed by a physician
  3. Prior receipt of varicella or zoster vaccine
  4. Exposure to varicella or herpes-zoster within the 4 weeks prior to the first vaccination
  5. Significant underlying illness preventing completion of the study vaccination schedules,
  6. Known active tuberculosis,
  7. Immune deficiency disorder, including active neoplastic disease within the prior 5 years,
  8. Immune function impairment caused by medical condition or therapy, or any other cause,
  9. Receipt of any inactivated vaccine within the 2 weeks prior to the first vaccination,
  10. Receipt of any other within the 4 weeks prior to the first vaccination,
  11. Receipt of immunoglobulins or blood-derived products within the 5 months prior to the first vaccination,
  12. Concomitant use of non-topical antiviral therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
759 participants (actual)

Study arms

  • Experimental
    Single Dose of Zostavax

    Zostavax 0.65mL intramuscular injection administered on Day 0

    Biological: Zostavax

  • Experimental
    Zostavax - Day 0 and Month 1

    Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1

    Biological: Zostavax

  • Experimental
    Zostavax - Day 0 and Month 3

    Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3

    Biological: Zostavax

Interventions

  • BiologicalZostavax

    Also known as: Zoster vaccine live

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3

    Blood samples taken at 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).

    Time frame: 4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)

Secondary outcomes

  1. Geometric Mean Titer (GMT) of VZV Antibodies 4 Weeks After Vaccination: Group 1

    Blood sample taken at 4 weeks post vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA.

    Time frame: 4 weeks post-dose (Month 1)

  2. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-vaccination to 4 Weeks Post-dose 1 in Groups 1, 2 and 3 and 4 Weeks Post-dose 2 in Groups 2 and 3

    Blood sample taken at predose (Day 0) and 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA. The GMFR was calculated following each vaccination as GMT Post-dose/GMT Pre-vaccination

    Time frame: Predose and 4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)

  3. Geometric Mean Titre of VZV Antibodies 12 Months Post-last Dose

    Blood sample taken at 1 year post last vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.

    Time frame: 1 year post final dose for Groups 1, 2, and 3 (Group 1: Month 12; Group 2: 13 Month 13; and Group 3: Month 15)

  4. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 3

    Blood sample taken at predose and 1 year post last vaccination to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was calculated for each arm as GMT 12-month post last dose divided by pre-vaccination GMT.

    Time frame: predose 1 and 1 year post-last dose (Group 1: Month 12; Group 2: 13 Month 13; and Group 3: Month 15)

  5. Geometric Mean Titre (GMT) of VZV Antibodies 24 and 36 Months Post-dose 1 in Group 1 and the 24 and 36 Months Post-dose 2 in Groups 2 and 3

    Blood sample taken at 36 months post last-vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.

    Time frame: 24 and 36 months post-last dose

  6. Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 24 And 36 Months Post-dose 1 in Group 1 and From Pre-vaccination To 24 And 36 Months Post-dose 2 in Groups 2 and 3

    Blood samples were to be taken at predose and 24 months post- last vaccination in Groups 1 , 2, and 3 to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was to be calculated for each arm as GMT 24-month post last dose divided by pre-vaccination GMT.

    Time frame: Predose 1 and 24 and 36 months post-last dose

  7. Percentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 1

    Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain

    Time frame: up to 4 days after 1st vaccination

  8. Percentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2

    Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain

    Time frame: up to 4 days after 2nd vaccination

  9. Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 1

    The percentage of participants who reported an injection site reaction that was not specifically prompted by the diary card within 28 day of 1st vaccination was recorded.

    Time frame: up to 28 days after 1st of study drug

  10. Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2

    The percentage of participants that reported an injection site reaction that was not specifically prompted by the diary card within 28 days post-dose 2 was recorded.

    Time frame: up to 28 days post-dose 2

  11. Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 1

    Percentage of participants who reported herpes zoster or zoster-like rash following the 1st dose of vaccine were recorded.

    Time frame: up to 28 days post-dose 1

  12. Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2

    Percentage of participants who reported herpes zoster or zoster-like rash following the 2nd dose of vaccine were recorded.

    Time frame: up to 28 days post-dose 2

  13. Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 1

    Percentage of participants that reported varicella or varicella-like rash following the 1st dose of vaccine were recorded.

    Time frame: up to 28 days post-dose 1

  14. Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2

    Percentage of participants that reported varicella or varicella-like rash following the 2nd dose of vaccine were recorded.

    Time frame: up to 28 days post-dose 2

  15. Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 1

    An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized

    Time frame: up to 28 days after 1st vaccination

  16. Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2

    An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized,

    Time frame: up to 28 days after 2nd vaccination

  17. Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 1

    An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized

    Time frame: up to 28 days after 1st vaccination

  18. Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2

    An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized,

    Time frame: up to 28 days after 2nd vaccination

  19. Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 1

    A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.

    Time frame: up to 28 days after 1st vaccination

  20. Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 2

    A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.

    Time frame: up to 28 days after 2nd vaccination

  21. Percentage of Participants Who Reported a Vaccine-related Serious Adverse Event

    A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE during the entire study period that was considered at least possibly -related to the vaccine were recorded.

    Time frame: up to end of study (approximately 15 months)

  22. Percentage of Participants Who Died During the Study

    The number of participants who died for any reason during the study was summarized.

    Time frame: up to end of study (approximately 15 months)

07

Results

Posted Dec 22, 2017

Participant flow

A total of 779 participants were screened. Twenty participants were not randomized.

Vaccination Period (up to Month 4)
Participant flow — Vaccination Period (up to Month 4)
MilestoneGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Started253255251
Received at least 1 vaccination253254250
Completed250229225
Not completed32626
Withdrew: Adverse event046
Withdrew: Definitive contra-indication023
Withdrew: Protocol violation013
Withdrew: Withdrawal by subject31613
Withdrew: Lost to follow-up010
Withdrew: Other021
12-month Post Last Dose Follow-up
Participant flow — 12-month Post Last Dose Follow-up
MilestoneGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Started250229225
Completed243220215
Not completed7910
Withdrew: Adverse event331
Withdrew: Protocol violation004
Withdrew: Withdrawal by subject265
Withdrew: Lost to follow-up200
24-month Post Last Dose Follow-up
Participant flow — 24-month Post Last Dose Follow-up
MilestoneGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Started000
Completed000
Not completed000
36 Month Post Last Dose Follow-up
Participant flow — 36 Month Post Last Dose Follow-up
MilestoneGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Started000
Completed000
Not completed000

Outcome measures

PrimaryGeometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3

Blood samples taken at 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via Glycoprotein Enzyme Linked Immunosorbent Assay (gpELISA).

Time frame:
4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titer (GMT) of Varicella Zoster Virus (VZV) Antibodies 4 Weeks After Each Vaccination: Groups 2 and 3
gpELISA units/mLGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Post Dose 1498.8 (438.7 to 567.1)523.3 (459.0 to 596.7)
Post Dose 2555.3 (496.6 to 620.9)410.5 (363.1 to 464.2)
Statistical analysis
  • Group 2: Zostavax - Day 0 and Month 1 · ANOVA · p = 0.948 · Geometric mean titer ratio (gmtr): 1.11 · 95% CI 1.02 to 1.22GMTR = GMT Post Dose 2/GMT Post dose 1
  • Group 3: Zostavax - Day 0 and Month 3 · ANOVA · p = >0.999 · Gmtr: 0.78 · 95% CI 0.73 to 0.85GMTR = GMT Post Dose 2/GMT Post dose 1
SecondaryGeometric Mean Titer (GMT) of VZV Antibodies 4 Weeks After Vaccination: Group 1

Blood sample taken at 4 weeks post vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA.

Time frame:
4 weeks post-dose (Month 1)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titer (GMT) of VZV Antibodies 4 Weeks After Vaccination: Group 1
gpELISA units/mLGroup 1: Single Dose of Zostavax
GMT Pre-Dose233.7 (207.1 to 263.7)
GMT Post Dose550.0 (489.2 to 618.4)
Statistical analysis
  • Group 1: Single Dose of Zostavax · Gmfr: 2.35 · 95% CI 2.11 to 2.62GMFR=GMT Post Dose/GMT Pre Dose
SecondaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-vaccination to 4 Weeks Post-dose 1 in Groups 1, 2 and 3 and 4 Weeks Post-dose 2 in Groups 2 and 3

Blood sample taken at predose (Day 0) and 4 weeks post each vaccination to determine the geometric mean titer (GMT) of VZV antibodies via gpELISA. The GMFR was calculated following each vaccination as GMT Post-dose/GMT Pre-vaccination

Time frame:
Predose and 4 weeks post-dose 1 (Month 1 for all groups) and 4 weeks post-dose 2 (Month 2 for Group 2 and Month 4 for Group 3)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-vaccination to 4 Weeks Post-dose 1 in Groups 1, 2 and 3 and 4 Weeks Post-dose 2 in Groups 2 and 3
gpELISA units/mLGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
GMFR Post Dose 12.35 (2.11 to 2.62)2.37 (2.11 to 2.66)2.29 (2.05 to 2.57)
GMFR Post Dose 2NA (NA to NA)2.64 (2.37 to 2.95)1.80 (1.63 to 1.98)
SecondaryGeometric Mean Titre of VZV Antibodies 12 Months Post-last Dose

Blood sample taken at 1 year post last vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.

Time frame:
1 year post final dose for Groups 1, 2, and 3 (Group 1: Month 12; Group 2: 13 Month 13; and Group 3: Month 15)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Titre of VZV Antibodies 12 Months Post-last Dose
gpELISA units/mLGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Geometric Mean Titre of VZV Antibodies 12 Months Post-last Dose246.8 (230.9 to 263.9)261.1 (242.8 to 280.7)266.6 (248.6 to 285.8)
Statistical analysis
  • Group 1: Single Dose of Zostavax vs Group 2: Zostavax - Day 0 and Month 1 · Gmt ratio: 1.06 · 95% CI 0.96 to 1.17GMT Ratio = Group 2 GMT/Group 1 GMT
  • Group 1: Single Dose of Zostavax vs Group 3: Zostavax - Day 0 and Month 3 · Gmt ratio: 1.08 · 95% CI 0.98 to 1.19GMT Ratio = GMT Group 3/GMT Group 1
SecondaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 3

Blood sample taken at predose and 1 year post last vaccination to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was calculated for each arm as GMT 12-month post last dose divided by pre-vaccination GMT.

Time frame:
predose 1 and 1 year post-last dose (Group 1: Month 12; Group 2: 13 Month 13; and Group 3: Month 15)
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 3
gpELISA units/mLGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Geometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 12 Months Post-dose 1 in Group 1 And From Pre-Vaccination To 12 Months Post-dose 2 in Groups 2 and 31.06 (0.99 to 1.14)1.16 (1.06 to 1.26)1.17 (1.07 to 1.27)
SecondaryGeometric Mean Titre (GMT) of VZV Antibodies 24 and 36 Months Post-dose 1 in Group 1 and the 24 and 36 Months Post-dose 2 in Groups 2 and 3

Blood sample taken at 36 months post last-vaccination to determine the geometric mean titer (GMT) of varicella antibodies via gpELISA.

Time frame:
24 and 36 months post-last dose

No measurements were reported for this outcome.

SecondaryGeometric Mean Fold Rise (GMFR) in VZV Antibody Titres From Pre-Vaccination To 24 And 36 Months Post-dose 1 in Group 1 and From Pre-vaccination To 24 And 36 Months Post-dose 2 in Groups 2 and 3

Blood samples were to be taken at predose and 24 months post- last vaccination in Groups 1 , 2, and 3 to determine the GMFR of varicella antibodies via gpELISA. Geometric mean fold rise was to be calculated for each arm as GMT 24-month post last dose divided by pre-vaccination GMT.

Time frame:
Predose 1 and 24 and 36 months post-last dose

No measurements were reported for this outcome.

SecondaryPercentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 1

Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain

Time frame:
up to 4 days after 1st vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Solicited Injection Site Reaction : Post-dose 147.246.042.2
SecondaryPercentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2

Participants entered data into daily dairy card regarding previously identified possible injection site reactions of erythema, injection site swelling or injection site pain

Time frame:
up to 4 days after 2nd vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Solicited Injection Site Reaction: Post-dose 2—42.242.1
SecondaryPercentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 1

The percentage of participants who reported an injection site reaction that was not specifically prompted by the diary card within 28 day of 1st vaccination was recorded.

Time frame:
up to 28 days after 1st of study drug
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 15.64.80.8
SecondaryPercentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2

The percentage of participants that reported an injection site reaction that was not specifically prompted by the diary card within 28 days post-dose 2 was recorded.

Time frame:
up to 28 days post-dose 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported an Unsolicited Injection Site Reaction: Post-dose 2—1.33.2
SecondaryPercentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 1

Percentage of participants who reported herpes zoster or zoster-like rash following the 1st dose of vaccine were recorded.

Time frame:
up to 28 days post-dose 1
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-dose 10.80.00.0
SecondaryPercentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2

Percentage of participants who reported herpes zoster or zoster-like rash following the 2nd dose of vaccine were recorded.

Time frame:
up to 28 days post-dose 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported Herpes Zoster or Zoster-like Rash: Post-Dose 2—0.00.0
SecondaryPercentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 1

Percentage of participants that reported varicella or varicella-like rash following the 1st dose of vaccine were recorded.

Time frame:
up to 28 days post-dose 1
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 10.00.00.0
SecondaryPercentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2

Percentage of participants that reported varicella or varicella-like rash following the 2nd dose of vaccine were recorded.

Time frame:
up to 28 days post-dose 2
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported Varicella or Varicella-like Rash: Post-dose 2—0.40.5
SecondaryPercentage of Participants Who Reported a Systemic Adverse Event: Post-dose 1

An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized

Time frame:
up to 28 days after 1st vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 125.832.725.7
SecondaryPercentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2

An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) were summarized,

Time frame:
up to 28 days after 2nd vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Systemic Adverse Event: Post-dose 2—20.715.4
SecondaryPercentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 1

An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized

Time frame:
up to 28 days after 1st vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 16.74.08.4
SecondaryPercentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2

An adverse event (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Adverse events that were considered systemic (not localized) and were reported as at least possibly related to the vaccine were summarized,

Time frame:
up to 28 days after 2nd vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Vaccine-related Systemic Adverse Event: Post-dose 2—3.42.7
SecondaryPercentage of Participants Who Reported a Serious Adverse Event: Post-dose 1

A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.

Time frame:
up to 28 days after 1st vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 1
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 10.42.80.4
SecondaryPercentage of Participants Who Reported a Serious Adverse Event: Post-dose 2

A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE within 28 days of 1st dose of vaccine were recorded.

Time frame:
up to 28 days after 2nd vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 2
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Serious Adverse Event: Post-dose 2—0.90.9
SecondaryPercentage of Participants Who Reported a Vaccine-related Serious Adverse Event

A serious adverse event (SAE) is any adverse event that results in death, is life threatening, results in a persistent or significant disability/incapacity, results in hospitalization or prolongs an existing hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose, or is considered an "other important medical event" based on medical judgement. The percentage of participants who reported an SAE during the entire study period that was considered at least possibly -related to the vaccine were recorded.

Time frame:
up to end of study (approximately 15 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Reported a Vaccine-related Serious Adverse Event
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Reported a Vaccine-related Serious Adverse Event0.00.00.0
SecondaryPercentage of Participants Who Died During the Study

The number of participants who died for any reason during the study was summarized.

Time frame:
up to end of study (approximately 15 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Died During the Study
Percentage of ParticipantsGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Percentage of Participants Who Died During the Study1.62.01.2

Adverse events

Collected over up to 1 year post-last dose (Group 1: 12 months total; Group 2: 13 months total; Group 3: 14 months total). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Single Dose of Zostavax—4/253 (1.6%)122/253 (48.2%)
Group 2: Zostavax - Day 0 and Month 1—11/255 (4.3%)144/255 (56.5%)
Group 3: Zostavax - Day 0 and Month 3—4/251 (1.6%)132/251 (52.6%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Myocardial infarctionCardiac disorders0/2532/2550/251
Coronary artery diseaseCardiac disorders0/2530/2551/251
DiverticulitisInfections and infestations0/2530/2551/251
Radius fractureInjury, poisoning and procedural complications0/2530/2551/251
Ulna fractureInjury, poisoning and procedural complications0/2530/2551/251
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2530/2551/251
Angina pectorisCardiac disorders1/2530/2550/251
Atrial fibrillationCardiac disorders1/2531/2550/251
Cardiac failureCardiac disorders1/2530/2550/251
DehydrationMetabolism and nutrition disorders1/2531/2550/251
Most frequent other events
Most frequent other events
EventGroup 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3
Injection site erythemaGeneral disorders107/253125/255122/251
Injection site painGeneral disorders57/25375/25574/251
Injection site swellingGeneral disorders69/25373/25567/251
HeadacheNervous system disorders13/25314/25510/251

Baseline characteristics

Baseline age missing for 1 participant in Group 2 and 1 participant in Group 3.

Age, Continuous
Age, Continuous(years)Group 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3Total
Mean76.2 ± 5.576.0 ± 5.476.1 ± 5.376.1 ± 5.4
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Single Dose of ZostavaxGroup 2: Zostavax - Day 0 and Month 1Group 3: Zostavax - Day 0 and Month 3Total
Female148138135421
Male105117116338
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Vesikari T, Hardt R, Rumke HC, Icardi G, Montero J, Thomas S, Sadorge C, Fiquet A. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax(R)) in individuals aged >/= 70 years: a randomized study of a single dose vs. two different two-dose schedules. Hum Vaccin Immunother. 2013 Apr;9(4):858-64. doi: 10.4161/hv.23412. Epub 2013 Jan 14. PubMed 23319176 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2007 to primary completion in Jun 2009, 19 months.

Results were first posted in Dec 2017, 8 years 6 months after primary completion.

Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 19 months is above that.

Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2007
First posted
Nov 20, 2007
StartActual
Oct 26, 2007
Primary completionActual
Jun 3, 2009
CompletionActual
Jun 3, 2009
Results first posted
Dec 22, 2017
Last update
Jan 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00561080
Responsible party
Sponsor
First posted
Nov 20, 2007
Start date
Oct 26, 2007
Primary completion
Jun 3, 2009
Completion
Jun 3, 2009
Results posted
Dec 22, 2017
Last update
Jan 11, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion